Westmore · UDRP DecisionBuyvaliumonlineuk.net
The Panel ordered transfer of <buyvaliumonlineuk.net>. It found the domain confusingly similar to the Complainant's well-known VALIUM trademark, that the Respondent lacked rights or legitimate interests, and that the domain had been registered and used in bad faith to attract Internet users for commercial gain through an online pharmacy website and sponsored links.
The timeline behind buyvaliumonlineuk.net
Registration, the decision and the archived record of what this domain actually displayed — from public RDAP and the Internet Archive.
Westmore reconstructs the full history behind buyvaliumonlineuk.net — from public RDAP and the Internet Archive — as part of UDRP Intelligence:
This decision illustrates strong UDRP targeting evidence where a well-known pharmaceutical mark is reproduced in full and combined with purchase, online-commerce, and geographic terms. The website content reinforced the domain's meaning, while the absence of a prominent relationship disclosure undermined any possible reseller or pharmacy-based claim to legitimacy.
Result of record. The panel's reasoning and decisive facts behind each element are in the Intelligence dossier below.
WIPO Arbitration and Mediation Center ADMINISTRATIVE PANEL DECISION F. Hoffmann-La Roche AG v. Whoisguard Protected / Sallu Org, Salman Baig Case No. D2014-0480 1. The Parties Complainant is F. Hoffmann-La Roche AG of Basel, Switzerland, represented internally. Respondent is Whoisguard Protected of Panama, Panama / Sallu Org, Salman Baig of Pishawar, Pakistan. 2. The Domain Name and Registrar The disputed domain name <buyvaliumonlineuk.net> is registered with eNom (the “Registrar”). 3. Procedural History The Complaint was filed with the WIPO Arbitration and Mediation Center (the “Center”) on March 26, 2014. On March 26, 2014, the Center transmitted by email to the Registrar a request for registrar verification in connection with the disputed domain name. On March 26, 2014, the Registrar transmitted by email to the Center its verification response disclosing registrant and contact information for the disputed domain name which differed from the named Respondent and contact information in the Complaint. The Center sent an email communication to the Complainant on April 1, 2014, providing the registrant and contact information disclosed by the Registrar, and inviting the Complainant to submit an amendment to the Complaint. The Complainant filed an amendment to the Complaint on April 2, 2014. The Center verified that the Complaint together with the amendment to the Complaint satisfied the formal requirements of the Uniform Domain Name Dispute Resolution Policy (the “Policy” or “UDRP”), the Rules for Uniform Domain Name Dispute Resolution Policy (the “Rules”), and the WIPO Supplemental Rules for Uniform Domain Name Dispute Resolution Policy (the “Supplemental Rules”). In accordance with the Rules, paragraphs 2(a) and 4(a), the Center formally notified Respondent of the Complaint, and the proceedings commenced on April 2, 2014. In accordance with the Rules, paragraph 5(a), the due date for Response was April 22, 2014. Respondent did not submit any response. Accordingly, the Center notified Respondent’s default on April 23, 2014. The Center appointed Manoel J. Pereira dos Santos as the sole panelist in this matter on May 26, 2014. The Panel finds that it was properly constituted. The Panel has submitted the Statement of Acceptance and Declaration of Impartiality and Independence, as required by the Center to ensure compliance with the Rules, paragraph 7. 4. Factual Background The trademark upon which the Complaint is based is VALIUM. According to the documentary evidence and contentions submitted, Complainant owns a number of registrations for the VALIUM trademark in different countries, including International Trademark registration No. 250784, with the registration date of December 20, 1961. According to the documentary evidence and contentions submitted, Complainant F. Hoffman-La Roche AG together with its affiliated companies is a leading healthcare supplier in the field of pharmaceuticals and diagnostic products operating in more than 100 countries. The disputed domain name was registered on January 12, 2014. The documentary evidence shows that the disputed domain name is used to resolve to a web page offering generic products identical to Complainant’s VALIUM products, and which are sold under Complainant’s VALIUM trademark. The Panel visited the website on May 30, 2014 and found out that such activity continues and that the website to which the disputed domain resolves does not accurately and prominently disclose the registrant's relationship with the trademark owner. 5. Parties’ Contentions A. Complainant Complainant contends that the disputed domain name is confusingly similar to the Complainant’s trademark because (i) it incorporates the VALIUM trademark in its entirety; (ii) the addition of the descriptive terms “buy” and “online” and of the geographic term “UK”(United Kingdom) does not sufficiently distinguish the domain name from Complainant’s mark; and (iii) the likelihood of confusion is increased by the fact that the VALIUM trademark is well-known. Complainant further contends that Respondent does not have rights or legitimate interests regarding the disputed domain name because (i) Complainant has not licensed, authorized or otherwise permitted Respondent to use the VALIUM trademark; and (ii) Respondent intends to use the disputed domain name for gain and to benefit from the reputation of the VALIUM trademark by redirecting to a webpage and pharmacy online. Finally, Complainant contends that Respondent registered and uses the disputed domain name in bad faith. According to Complainant, (i) Respondent registered the disputed domain name in bad faith because at the time of the registration Respondent knew of the existence of the VALIUM trademark; (ii) Respondent is using the disputed domain name to attract Internet users to its website and to obtain commercial gain from the false impression with regard to an association/affiliation with Complainant; and (iii) Respondent is illegitimately capitalizing on the VALIUM trademark fame ad generating unjustified revenues for each click-through by on-line consumers of the sponsored links. B. Respondent The Respondent did not reply to the Complainant’s contentions. 6. Discussion and Findings A. Effect of the Default The consensus view of UDRP panels is that a respondent’s default does not automatically result in a decision in favor of the complainant and that a complainant must establish each of the three elements required by paragraph 4(a) of the UDRP. WIPO Overview of WIPO Panel Views on Selected UDRP Questions, Second Edition (“WIPO Overview 2.0”), paragraph 2.2. However, paragraph 14(b) of the Rules provides that, in the absence of exceptional circumstances, a panel shall draw such inferences as it considers appropriate from a failure of a party to comply with a provision or requirement of the Rules. The Panel finds that there are no exceptional circumstances in this case for the failure of Respondent to submit a Response. As a result, the Panel infers that Respondent does not deny the facts asserted and contentions made by Complainant from these facts. Reuters Limited v. Global Net 2000, Inc. , WIPO Case No. D2000-0441 ; LCIA (London Court of International Arbitration) v. Wellsbuck Corporation, WIPO Case No. D2005-0084 ; Ross-Simons, Inc. v. Domain.Contact, WIPO Case No. D2003-0994 .Therefore, asserted facts that are not unreasonable will be taken as true and Respondent will be subject to the inferences that flow naturally from the information provided by Complainant. Reuters Limited v. Global Net 2000, Inc. , supra ; RX America, LLC v. Matthew Smith , WIPO Case No. D2005-0540 . The Panel will now review each of the three cumulative elements set forth in paragraph 4(a) of the Policy to determine whether Complainants have complied with such requirements. B. Identical or Confusingly Similar The disputed domain name <buyvaliumonlineuk.net> incorporates the VALIUM trademark in its entirety. Previous UDRP panels have held that when a domain name wholly incorporates a Complainant’s registered trademark that may be sufficient to establish confusing similarity for purposes of the Policy. See , e.g., Telstra Corporation v. Barry Cheng Kwok Chu , WIPO Case No. D2000-0423 ; Pfizer Inc. v. United Pharmacy Ltd , WIPO Case No. D2001-0446 ; E.I. du Pont de Nemours and Company v. Richi Industry S. r. l., WIPO Case No. D2001-1206 ; Utensilerie Associate S. p. A. v. C & M, WIPO Case No. D2003-0159 ; Lilly Icos LLC . v. John Hopking/ Neo net Ltd. , WIPO Case No. D2005-0694 ; Shaw Industries Group Inc., Columbia Insurance Company v. Wan-Fu China, Ltd. , WIPO Case No. D2007-0282 . That is particularly true where the trademark is highly recognizable as in the instant case. In fact, previous UDRP decisions have found that the VALIUM trademark is well-known and this Panel concurs with such finding. See, e.g., F. Hoffmann-La Roche AG v. Med2shop, Thomas Donald Stenzel, WIPO Case No. D2013-2120 ; F. Hoffmann-La Roche AG v. N/A, tomson eneriho , WIPO Case No. D2013-0483 . Further, it has been decided that the addition of generic or descriptive terms to an otherwise distinctive trademark name is to be considered confusingly similar to the registered trademark. V&S Vin&Sprit AhB v. Giovanni Pastore , WIPO Case No. D2002-0926 ; Thomson Broadcast and Media Solution Inc., Thomson v. Alvaro Collazo , WIPO Case No. D2004-0746 ; Sanofi-Aventis v. US-Meds.com, WIPO Case No. D2004-0809 ; and F. Hoffman La Roche AG v.Pinetree Development, Ltd., WIPO Case No. D2006-0049 . In the instant case, the combination of the word “valium” with the generic words “buy” and “online” does not affect the overall impression of the dominant part of the disputed domain name. In fact, several previous UDRP decisions have held that the addition of common words does not distinguish a domain name from Complainant’s trademark or preclude a finding of confusing similarity. See , e.g., Hoffmann–La Roche Inc. v. Hightech Industries, Andrew Browne, WIPO Case No. D2010-0240 ; Wal-Mart Stores, Inc. v. Richard MacLeod d/b/a For Sale, WIPO Case No. D2000-0662 . Also, the addition of the geographic term “UK” reinforces the misleading association with the VALIUM trademark as such words may be understood as meaning “buy Valium on line [at] UK”. Finally, the addition of generic top-level domain suffix “.net” is non-distinctive in this case because it is a simple requirement for the registration of the domain name. RX America, LLC v. Mattew Smith , WIPO Case No. D2005-0540 ; Sanofi-Aventis v. US Online Pharmacies , WIPO Case No. D2006-0582 . Therefore, the Panel finds that the disputed domain name is confusingly similar to the VALIUM trademark and, as a result, finds that the requirement of paragraph 4(a)(i) of the Policy is met. C. Rights or Legitimate Interests The consensus view of URDP panels is that a complainant is required to make out an initial prima facie case, after which the respondent carries the burden of demonstrating its rights or legitimate interests in the domain name. If the respondent fails to do so, the complainant is deemed to have satisfied paragraph 4(a)(ii) of the UDRP. WIPO Overview 2.0 , paragraph 2.1. In the instant case, Complainant has done enough to establish a prima facie case. The Panel finds reasonable Complainant’s contentions that Respondent has never been licensed, authorized or otherwise permitted to use the disputed domain name. The Panel also finds that Respondent’s use of the disputed domain name does not satisfy the test for bona fide use established in prior UDRP decisions as the disputed domain name is being used to host a website offering generic products identical to Complainant’s VALIUM products, which are sold under Complainant’s VALIUM trademark, and that such website does not accurately and prominently disclose the registrant's relationship with the trademark owner. The issue as to whether use of a domain name for purposes of offering “sponsored links” creates a legitimate right to a domain name has been addressed in previous UDRP decisions. There is a consensus view that such use cannot be considered a bona fide offering of goods or services, or a noncommercial or fair use, when a respondent is in fact capitalizing on someone else’s trademark value. See Bridgestone Corp. v. Horoshiy, Inc., WIPO Case No. D2004-0795 ; Deutsche Telekom AG v. Dong Wong , WIPO Case No. D2005-0819 ; and PRL USA Holdings, Inc. v. LucasCobb, WIPO Case No. D2006-0162 . In short, the contents of the site to which the disputed domain name resolves and the explicit use of the VALIUM trademark by Respondent support a finding that Respondent lacks rights or legitimate interests in the disputed domain name. In light of the foregoing, the Panel finds that the requirement of paragraph 4(a)(ii) of the Policy is met. D. Registered and Used in Bad Faith Complainants’ first contention of bad faith is based on the argument that at the time of the registration of the disputed domain name Respondent knew of the existence of the VALIUM trademark. In view of the particulars of the instant case, the Panel finds that Respondent was undoubtedly aware of the existence of Complainant’s VALIUM trademark when it registered the disputed domain name. In fact, the Panel sees no plausible explanation for Respondent’s association of the word “valium” ” with the generic words “buy” and “online” as well as with the geographic word “UK” to form a domain name that may be understood as meaning “buy Valium on line [at] UK” other than to attract for commercial gain Internet users by creating a likelihood of confusion with the Complainant’s trademark. See Madonna Ciccone, p/k/a Madonna v. Dan Parisi and "Madonna.com" , WIPO Case No. D2000-0847 . Therefore, the Panel finds that that the disputed domain name was selected and is used by Respondent to take advantage of the notoriety and good will associated with the VALIUM trademark, with the intent to attract for commercial gain Internet users by utilizing sponsored links. The Panel concurs with the understanding of several other UDRP panels that the use of a domain name to point to a website that offers sponsored links to competing websites is evidence of bad faith, particularly if, as in the instant case, Complainant owns a well-known trademark. See Mudd, LLC v. Unasi, Inc. , WIPO Case No. D2005-0591 ; and Volvo Trademark Holding AB v. Unais, Inc. , WIPO Case No. D2005-0556 . As a matter of fact, in the case of a domain name so obviously connected to a registered mark, its use by someone with no legitimate interest in respect of the registered domain name constitutes what has been called as “opportunistic bad faith”. See SSL International PLC v. Mark Freeman , WIPO Case No. D2000-1080 ; Perfumes Christian Dior v. Javier Garcia Quintas and Christian Dior. net , WIPO Case No. D2000-0226 ; Veuve Clicquot Ponsardin, Maison Fondée en 1772 v. The Polygenix Group Co. , WIPO Case No. D2000-0163 . In short, the manner in which Respondent has registered and is using the disputed domain name demonstrates that the disputed domain name was registered and is being used in bad faith. In light of all the conclusions and findings above, the Panel finds that the requirement of paragraph 4(a)(iii) of the Policy is met. 7. Decision For the foregoing reasons, in accordance with paragraphs 4(i) of the Policy and 15 of the Rules, the Panel orders that the disputed domain name <buyvaliumonlineuk.net> be transferred to the Complainant. Manoel J. Pereira dos Santos Sole Panelist Date: June 9, 2014
Source of record: WIPO . Reproduced for research; WIPO is the authoritative source.
What Westmore sees around buyvaliumonlineuk.net
The decision is only the record. Westmore connects it to the cases, authorities, panelists, parties and domain evidence surrounding it.
A short, grounded explanation drawn only from this decision's record — not legal advice or a prediction.
Grounded in the Westmore record for this decision. Research/informational only — not legal advice or a prediction of any outcome.
The decision is only the beginning.
You've seen what happened. Now discover the deeper intelligence behind the case, the panelist, the parties and the authorities that matter.
Go beyond the public record: see how this case has been cited, find comparable decisions, analyze the panelist and apply the relevant authorities to your Matter.
Westmore Professional · $395/month
Research with UDRP IntelligenceWestmore AI drafts an attorney-review-ready UDRP response from your facts, grounded in the exact panel and closest precedent.
$895 one-time per matter · no subscription required. Self-help drafting aid — not legal advice.
Build your responseWestmore UDRP records draw on WIPO-indexed decisions and are provided for research and informational purposes only. Not legal advice, a clearance opinion, or a prediction of any outcome.